Skip to Content

Inspire Announces Poster Presentations at 2008 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

DURHAM, N.C.--(BUSINESS WIRE)--Mar 14, 2008 - Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Inspire scientists and collaborators will present information in two poster presentations at the 2008 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting being held March 14 - 18, 2008 in Philadelphia.

The poster entitled "Pharmacokinetic Model of Epinastine, an H1 Antagonist, after Nasal Administration" (C. Crean, P. Ratner, M. Widmann, A. Schaberg, D. Kellerman) contains data from Inspire's Phase 2 trial with epinastine nasal spray for the treatment of Seasonal Allergic Rhinitis (SAR). The poster focuses on modeling the systemic absorption of epinastine when administered nasally and a comparison to oral delivery.

The second poster entitled "The Use of Oral Antihistamines (OA) in Moderate to Severe Dry Eye Patients" (D. Kellerman, T. Durham, A. Schaberg, K. Kuhn, A. Woodring, K. Brazzell, G. Foulks, E. Meltzer) contains data from Inspire's Phase 3 program with Prolacria(TM) (diquafosol tetrasodium) for the treatment of dry eye. The poster is related to the incidence of use of oral antihistamines by patients with moderate to severe dry eye from the clinical trials.

The posters will be available following the conference on Inspire's website,

About Inspire

Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. Inspire employs a U.S. sales force for the promotion of AzaSite(R) (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is focused on the therapeutic areas of ophthalmology and respiratory/allergy, and is developing products for dry eye, cystic fibrosis, allergic rhinitis and glaucoma. Elestat and Restasis are registered trademarks owned by Allergan, Inc. AzaSite is a registered trademark owned by InSite Vision Incorporated. For more information, visit


Investor Contact:
Inspire Pharmaceuticals, Inc.
Jenny Kobin
VP, Investor Relations and Corporate Communications
919-941-9777, ext. 219
Media Contact:
BMC Communications
Dan Budwick, 212-477-9007, ext. 14

Posted: March 2008